Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma

Chamseddine S, LaPelusa M, Xiao L, Mohamed YI, Lee SS, Hu ZI, Hatia RI, Hassan M, Yao JC, Duda DG, Datar S, Amin HM, Kaseb AO

Journal of Hepatocellular Carcinoma 2024, 11:455-461

Published Date: 4 March 2024